Floatz logo

Anti-Cd19/Cd20/Cd22 Car T-Cells

Recurrent B Acute Lymphoblastic Leukemia

Sumithira VasuCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Recurrent B Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
(+)-VINCRISTINE
SWOG Cancer Research Network
Phase 3BB
PEGFILGRASTIM
University of Washington
Phase 2B
Nivolumab
Assistance Publique - Hôpitaux de Paris
Phase 2B
Mitoxantrone
National Cancer Institute (NCI)
Phase 3B

View all 24 →

Same molecule, other indications

Anti-Cd19/Cd20/Cd22 Car T-Cells is also rated in:

Recurrent B-Cell Prolymphocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent High Grade B-Cell LymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →